brimonidine tartrate has been researched along with Cranial Nerve II Diseases in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lindsley, K; Sena, DF | 2 |
| Kitaoka, Y; Kojima, K; Munemasa, Y; Sase, K; Takagi, H | 1 |
| Cheng, JW; Li, Y; Wei, RL | 1 |
| Cheng, CY; Chiu, AW; Chou, JC; Hsu, WM; Ko, YC; Liu, CJ; Liu, JH | 1 |
| Aloni, E; Bakalash, S; Ben Simon, GJ; Rosner, M | 1 |
| Aston, SJ; Capel, B; Capell, BC; Chiu, ES; Jelks, EB; Jelks, GW; Press, R | 1 |
| Krupin, T | 1 |
| Schwartz, M; Wheeler, LA; Yoles, E | 1 |
| Ainsworth, J; Kulshrestha, M; Ng, S; Roff, E; Sedgwick, G | 1 |
4 review(s) available for brimonidine tartrate and Cranial Nerve II Diseases
| Article | Year |
|---|---|
Neuroprotection for treatment of glaucoma in adults.
Topics: Adult; Antihypertensive Agents; Brimonidine Tartrate; Disease Progression; Glaucoma, Open-Angle; Humans; Neuroprotective Agents; Optic Nerve; Optic Nerve Diseases; Quinoxalines; Randomized Controlled Trials as Topic; Retinal Ganglion Cells; Timolol | 2013 |
Neuroprotection for treatment of glaucoma in adults.
Topics: Adult; Antihypertensive Agents; Brimonidine Tartrate; Disease Progression; Glaucoma, Open-Angle; Humans; Neuroprotective Agents; Optic Nerve; Optic Nerve Diseases; Randomized Controlled Trials as Topic; Retinal Ganglion Cells; Timolol | 2017 |
Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Databases, Factual; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Optic Nerve Diseases; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiazines; Thiophenes; Timolol | 2009 |
Successful management of orbital cellulitis and temporary visual loss after blepharoplasty.
Topics: Abscess; Adult; Anti-Bacterial Agents; Blepharoplasty; Blindness; Brimonidine Tartrate; Cavernous Sinus Thrombosis; Cellulitis; Clindamycin; Combined Modality Therapy; Decompression, Surgical; Dexamethasone; Drainage; Emergencies; Exophthalmos; Female; Gentamicins; Humans; Latanoprost; Nerve Compression Syndromes; Occupational Exposure; Optic Nerve Diseases; Orbital Diseases; Penicillins; Prostaglandins F, Synthetic; Quinoxalines; Streptococcal Infections; Streptococcus pyogenes; Surgical Wound Infection; Teaching; Timolol; Vancomycin; Vision Disorders | 2006 |
2 trial(s) available for brimonidine tartrate and Cranial Nerve II Diseases
| Article | Year |
|---|---|
Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Brimonidine Tartrate; Cross-Over Studies; Drug Evaluation; Eye; Female; Glaucoma, Open-Angle; Heart Rate; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Optic Disk; Optic Nerve Diseases; Prostaglandins F, Synthetic; Quinoxalines; Vision Disorders; Visual Fields | 2002 |
Special considerations in low-tension glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Neuroprotective Agents; Optic Nerve Diseases; Quinoxalines; Retinal Ganglion Cells; Timolol; Vision Disorders; Visual Field Tests; Visual Fields | 2007 |
4 other study(ies) available for brimonidine tartrate and Cranial Nerve II Diseases
| Article | Year |
|---|---|
Axonal protection by brimonidine with modulation of p62 expression in TNF-induced optic nerve degeneration.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Axons; Brimonidine Tartrate; Cell Count; Disease Models, Animal; Heat-Shock Proteins; Immunoblotting; Immunoenzyme Techniques; Intravitreal Injections; Male; Nerve Degeneration; Optic Nerve Diseases; Rats; Rats, Wistar; Sequestosome-1 Protein; Tumor Necrosis Factor-alpha | 2015 |
A rat model for acute rise in intraocular pressure: immune modulation as a therapeutic strategy.
Topics: Acute Disease; Animals; Antihypertensive Agents; Brimonidine Tartrate; Cell Survival; Disease Models, Animal; Dizocilpine Maleate; Glatiramer Acetate; Immunization; Injections; Intraocular Pressure; Male; Neuroprotective Agents; Ocular Hypertension; Optic Nerve Diseases; Peptides; Quinoxalines; Rats; Rats, Inbred Lew; Retinal Ganglion Cells; Vaccination | 2006 |
Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration.
Topics: Action Potentials; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Axons; Brimonidine Tartrate; Cell Count; Cell Survival; Clonidine; Disease Models, Animal; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Male; Nerve Degeneration; Neuroprotective Agents; Optic Nerve; Optic Nerve Diseases; Optic Nerve Injuries; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Retinal Ganglion Cells; Timolol; Yohimbine | 1999 |
Demonstration of the reversibility of optic disc topography by scanning laser ophthalmoscopy.
Topics: Adrenergic alpha-Agonists; Aniridia; Brimonidine Tartrate; Child; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Lasers; Latanoprost; Male; Ophthalmoscopy; Optic Disk; Optic Nerve Diseases; Prostaglandins F, Synthetic; Quinoxalines; Trabeculectomy; Visual Acuity | 1999 |